Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage and to a reduction of joint function and poor quality of life. Treatment of PsA has changed since its introduction of anti- TNF drugs, which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. However, recently, the discovery of new pathogenic mechanisms have made possible the development of new molecules that target pro-inflammatory cytokines involved in skin, joint and entheseal inflammation. New drugs like ustekinumab, secukinumab and apremilast inhibit interleukin axis and intracellular pathways and showed their efficacy and safety in randomized clinical trials. These drugs have been recently approved for the treatment of PsA and included in the new EULAR and GRAPPA treatment recommendations. The aim of this paper is to briefly review the clinical trials that led to their approval for PsA.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.4081/reumatismo.2016.873|
|Codice identificativo ISI:||WOS:000388231100001|
|Codice identificativo Scopus:||2-s2.0-84986877448|
|Titolo:||New approved drugs for psoriatic arthritis.|
|Appare nelle tipologie:||1.1 Articolo in rivista|